Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) is one of the best strong buy stocks to invest in according to Wall Street. On September 24, JPMorgan analyst Jessica Fye lowered the firm’s price target on Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) to $52 from $53 while keeping an Overweight rating on the shares. Is Crinetics Pharmaceuticals Inc. (CRNX) the Worst Performing Mid Cap Stock to Buy According to Analysts? The firm told investors that it updated Crinetics Pharmaceuticals, Inc.’s (NASDAQ:CRNX) ...